Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 35

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 35
---
, the adverse market and price pressures resulting from an offering pursuant to the registration statement may continue for an extended period of time. Sales of substantial number of such shares in the public market, including the resale of the shares of Common Stock held by the Selling Securityholder, could adversely affect the market price of our Common Stock. In addition to this prospectus, we have filed:

| ● | a registration statement with the SEC for purposes of registering the resale from time to time of up to 105,000 Shares of Common Stock, which consists of (i) 104,318 shares of Common Stock under the March 2024 Keystone Purchase Agreement and (ii) 682 shares of Common Stock under the February 2024 Keystone Purchase Agreement; |

| ● | a registration statement with the SEC for purposes of registering the resale from time to time of up to 13,310 Shares of Common Stock, which consists of (i) 12,500 Keystone Purchase Shares, (ii) 310 Keystone Commitment Shares, and (iii)  500 Arena Commitment Shares; |

12

| ● | a registration statement with the SEC for purposes of registering (1)                                                                          
 the resale from time to time of up to 17,887 shares of Common Stock, which consists of (i) 1,028 shares of Common Stock issued to certain      
 selling securityholders for their portion of the merger consideration in connection with the consummation of the Business Combination          
 in exchange for shares of common stock of Legacy CERo; (ii) 10,040 shares of Common Stock issuable upon the conversion of shares of our        
 Series A Preferred Stock, purchased by certain investors pursuant to the First Securities Purchase Agreement; (iii) 626 shares of Common       
 Stock issuable upon the conversion of shares of our Series B Preferred Stock, purchased by certain investors pursuant to the Second Securities 
 Purchase Agreement; (iv) 1,586 shares of Common Stock initially issued to the Sponsor and distributed to its members in a distribution-in-kind 
 immediately prior to the Business Combination; (v) 500 shares of Common Stock issued to the Sponsor, which are subject to forfeiture upon      
 the vesting of the Tertiary Earnout Shares; (vi) 93 shares of Common Stock issued to investors other than the Sponsor in a private placement   
 concurrently with the Initial Public Offering; (vii) 825 shares of our Common Stock issued to certain third-party vendors and service          
 providers; (viii) 162 shares of Common Stock issuable